



September 16, 2025

Expiration of Co-Promotion Agreement for STELARA® (ustekinumab)

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, CEO: Akihisa Harada, "MTPC") will conclude co-promotion activities for the human anti-human IL-12/23p40 monoclonal antibody formulation "Stelara®" (generic name: ustekinumab; (genetically modified)), which is manufactured and marketed by Janssen Pharmaceutical K.K. ("Janssen"), due to the expiration of the contract period, effective December 31, 2025.

Based on the co-promotion agreement for STELARA® in Japan between MTPC and Janssen, MTPC has been responsible for distribution in Japan, while both MTPC and Janssen have jointly conducted promotion of STELARA® to healthcare professionals. After the expiration of the current contract period, Janssen will exclusively handle the sales, distribution, and information provision activities for STELARA®.

Furthermore, following the contract expiration on December 31, 2025, MTPC will continue the distribution of "Stelara®" bearing the MTPC name until the inventory is depleted.

MTPC will continue to contribute to disease prevention and treatment, and to the well-being of individuals by ensuring stable supply of medical pharmaceuticals and providing prompt and appropriate information activities.

<p><i>Contact:</i> Mitsubishi Tanabe Pharma Corporation CEO Office PR Group +81-6-6205-5119</p>
